DO
Therapeutic Areas
Gilead Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lenacapavir | HIV-1 Treatment & Prevention | Approved / Phase 3 |
| Selgantolimod (GS-9688) | Chronic Hepatitis B | Phase 2 |
| Bulevirtide (Hepcludex) | Chronic Hepatitis D | Approved (EU) / Phase 3 (US) |
| Trodelvy (sacituzumab govitecan) | Metastatic HR+/HER2- Breast Cancer, NSCLC | Approved / Phase 3 |
| Yescarta (axi-cel) | Large B-cell Lymphoma | Approved / Phase 3 |
| Domvanalimab + Zimberelimab | 1L Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
| GS-1811 | Solid Tumors | Phase 1 |
| Filgotinib (JYSELECA) | Ulcerative Colitis, Crohn's Disease | Approved (RA) / Phase 3 |